Format

Send to

Choose Destination
Eur J Pharm Sci. 2019 Oct 1;138:105031. doi: 10.1016/j.ejps.2019.105031. Epub 2019 Aug 3.

Combining biorelevant in vitro and in silico tools to simulate and better understand the in vivo performance of a nano-sized formulation of aprepitant in the fasted and fed states.

Author information

1
Institute of Pharmaceutical Technology, Goethe University, Frankfurt am Main, Germany.
2
Certara UK Limited, Simcyp Division, Level 2-Acero, 1 Concourse Way, Sheffield S1 2BJ, UK.
3
University of Applied Sciences and Arts Northwestern Switzerland, Gründenstr. 40, 4132, Switzerland.
4
Pion Inc. (UK) Ltd., Forest Row, East Sussex, UK.
5
Institute of Pharmaceutical Technology, Goethe University, Frankfurt am Main, Germany. Electronic address: dressman@em.uni-frankfurt.de.

Abstract

INTRODUCTION:

When developing bio-enabling formulations, innovative tools are required to understand and predict in vivo performance and may facilitate approval by regulatory authorities. EMEND® is an example of such a formulation, in which the active pharmaceutical ingredient, aprepitant, is nano-sized. The aims of this study were 1) to characterize the 80 mg and 125 mg EMEND® capsules in vitro using biorelevant tools, 2) to develop and parameterize a physiologically based pharmacokinetic (PBPK) model to simulate and better understand the in vivo performance of EMEND® capsules and 3) to assess which parameters primarily influence the in vivo performance of this formulation across the therapeutic dose range.

METHODS:

Solubility, dissolution and transfer experiments were performed in various biorelevant media simulating the fasted and fed state environment in the gastrointestinal tract. An in silico PBPK model for healthy volunteers was developed in the Simcyp Simulator, informed by the in vitro results and data available from the literature.

RESULTS:

In vitro experiments indicated a large effect of native surfactants on the solubility of aprepitant. Coupling the in vitro results with the PBPK model led to an appropriate simulation of aprepitant plasma concentrations after administration of 80 mg and 125 mg EMEND® capsules in both the fasted and fed states. Parameter Sensitivity Analysis (PSA) was conducted to investigate the effect of several parameters on the in vivo performance of EMEND®. While nano-sizing aprepitant improves its in vivo performance, intestinal solubility remains a barrier to its bioavailability and thus aprepitant should be classified as DCS IIb.

CONCLUSIONS:

The present study underlines the importance of combining in vitro and in silico biopharmaceutical tools to understand and predict the absorption of this poorly soluble compound from an enabling formulation. The approach can be applied to other poorly soluble compounds to support rational formulation design and to facilitate regulatory assessment of the bio-performance of enabling formulations.

KEYWORDS:

Aprepitant; Bio-enabling formulations; Modeling and simulation; Nano-sized drugs; PBPK

PMID:
31386891
DOI:
10.1016/j.ejps.2019.105031

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center